Who
Raymond Prudo-Chlebosz
Director
Company insider
Files Form 4 as: Director, Akari Therapeutics.
In numbers
- Trades disclosed
- 18
- Buys
- 0
- Sells
- 0
- Bought
- $0
- Sold
- $0
- Companies
- 1
- Companies where not an officer
- 1
- First trade
- 31 May 2024
- Last trade
- 5 Oct 2026
- Last filed
- 16 Oct 2026
Companies traded
Activity over time
Not enough dated trades to draw.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 5 Oct 2026filed 16 Oct 2026 | AKTX Akari TherapeuticsBiotechnology | SEC FORM 4 Code A | $26K3,240 at $7.90 | filing |
| 18 Aug 2026filed 16 Oct 2026 | AKTX Akari TherapeuticsBiotechnology | SEC FORM 4 Code A | $72K9,072 at $7.90 | filing |
| 18 Aug 2026filed 16 Oct 2026 | AKTX Akari Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —30,000 at $0.00 | filing |
| 18 Aug 2026filed 16 Oct 2026 | AKTX Akari Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —15,000 at $0.00 | filing |
| 16 Dec 2025filed 18 Dec 2025 | AKTX Akari Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code P | —618,658 | filing |
| 16 Dec 2025filed 18 Dec 2025 | AKTX Akari Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code P | $247K618,658 at $0.40 | filing |
| 16 Dec 2025filed 18 Dec 2025 | AKTX Akari Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code P | —386,661 | filing |
| 16 Dec 2025filed 18 Dec 2025 | AKTX Akari Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code P | $155K386,661 at $0.40 | filing |
| 20 Mar 2025filed 24 Mar 2025 | AKTX Akari Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —175,000 at $0.00 | filing |
| 20 Mar 2025filed 24 Mar 2025 | AKTX Akari Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —225,000 at $0.00 | filing |
| 6 Mar 2025filed 10 Mar 2025 | AKTX Akari Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | $500K446,428 at $1.12 | filing |
| 6 Mar 2025filed 10 Mar 2025 | AKTX Akari Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | $500K446,428 at $1.12 | filing |
| 6 Mar 2025filed 10 Mar 2025 | AKTX Akari TherapeuticsBiotechnology | SEC FORM 4 Code A | $500K446,428 at $1.12 | filing |
| 2 Dec 2024filed 3 Dec 2024 | AKTX Akari Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —419,286,000 at $0.00 | filing |
| 2 Dec 2024filed 3 Dec 2024 | AKTX Akari TherapeuticsBiotechnology | SEC FORM 4 Code A | —419,286,000 at $0.00 | filing |
| 28 Jun 2024filed 2 Jul 2024 | AKTX Akari Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —10,000,000 at $0.00 | filing |
| 31 May 2024filed 4 Jun 2024 | AKTX Akari Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —1,326,258,000 at $0.00 | filing |
| 31 May 2024filed 4 Jun 2024 | AKTX Akari TherapeuticsBiotechnology | SEC FORM 4 Code A | —1,326,258,000 at $0.00 | filing |
News
No headline names them, or the companies they trade most, lately.
Sectors
No trade we could place in a sector.